Oxygen Dependence and Extravascular Transport of Hypoxia-Activated Prodrugs: Comparison of the Dinitrobenzamide Mustard PR-104A and Tirapazamine

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 560-571

  Hicks, Kevin O ^a   Myint, Hilary ^a   Patterson, Adam V ^a   Pruijn, Frederik B ^a   Siim, Bronwyn G ^a   Patel, Kashyap ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Extravascular drug transport; Hypoxia activated prodrugs; Multicellular layers; PR 104; Tirapazamine; Tumor hypoxia

Indexed keywords

EXTRAVASCULAR DRUG TRANSPORT; HYPOXIA ACTIVATED PRODRUGS; MULTICELLULAR LAYERS; TIRAPAZAMINES; TUMOR HYPOXIA;

AMIDES; AMINES; CYTOTOXICITY; OXYGEN; PHARMACOKINETICS; RADIOTHERAPY; TISSUE;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; NITROBENZENE DERIVATIVE; OXYGEN; PR 104A; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; HYPOXIC CELL; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL HYPOXIA; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NITROGEN MUSTARD COMPOUNDS; OXYGEN; PARTIAL PRESSURE; PRODRUGS; RADIATION-SENSITIZING AGENTS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 34548513083     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.049     Document Type: Article

References (46)

1. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
2. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
3. 2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60 (2002) 634-639
4. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
5. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8 (2001) 739-761
6. Brown J.M., and Wilson W.R. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
7. Haffty B.G., Wilson L.D., Son Y.H., et al. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 61 (2005) 119-128
8. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
9. Patterson L.H., and McKeown S.R. AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83 (2000) 1589-1593
10. Patterson A.V., Ferry D.M., Edmunds S.J., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 13 (2007) 3922-3932
11. Papadopoulou M.V., and Bloomer W.D. NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9 (2003) 5714-5720
12. Durand R.E., and Olive P.L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Invest 5 (1997) 213-219
13. Hicks K.O., Fleming Y., Siim B.G., et al. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42 (1998) 641-649
14. Kyle A.H., and Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43 (1999) 213-220
15. Hicks K.O., Pruijn F.B., Secomb T.W., et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 98 (2006) 1118-1128
16. Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53 (1993) 3992-3997
17. Hicks K.O., Siim B.G., Pruijn F.B., et al. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat Res 161 (2004) 656-666
18. Davis PD, Naylor MA, Thomson P, et al. Bioreductively-activated prodrugs. PCT publication WO 0603921 A1 (Angio-Gene Pharmaceuticals Ltd and The Gray Laboratory, Cancer Research Trust). 2006.
19. Taylor Y.C., and Rauth A.M. Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res 91 (1982) 104-123
20. Marshall R.S., and Rauth A.M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res 48 (1988) 5655-5659
21. Wilson W.R., Moselen J.W., Cliffe S., et al. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: The cobalt(III)-nitrogen mustard complex SN 24771. Int J Radiat Oncol Biol Phys 29 (1994) 323-327
22. Siim B.G., Atwell G.J., and Wilson W.R. Oxygen dependence of the cytotoxicity and metabolic activation of 4- alkylamino-5-nitroquinoline bioreductive drugs. Br J Cancer 70 (1994) 596-603
23. Ling C.C., Michaels H.B., Gerwick L.E., et al. Oxygen sensitization of mammalian cells under different irradiation conditions. Radiat Res 86 (1981) 325-340
24. Whillans D.W., and Hunt J.W. A rapid-mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells. Radiat Res 90 (1982) 126-141
25. Horan A.D., and Koch C.J. The K(m) for radiosensitization of human tumor cells by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat Res 156 (2001) 388-398
26. Wouters B.G., and Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147 (1997) 541-550
27. Lee A.E., and Wilson W.R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 163 (2000) 50-59
28. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
29. Parmar K., Mauch P., Vergilio J., et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104 (2007) 5431-5436
30. Wilson W.R., Hicks K.O., Pullen S.M., et al. Bystander effects of bioreductive drugs: Potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 167 (2007) 625-636
31. Atwell G.J., Yang S., Pruijn F.B., et al. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5 mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. J Med Chem 50 (2007) 1197-1212
32. Hay M.P., Gamage S.A., Kovacs M.S., et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 46 (2003) 169-182
33. Koch C.J. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 352 (2002) 3-31
34. Hicks K.O., Pruijn F.B., Sturman J.R., et al. Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 63 (2003) 5970-5977
35. Patel K., Gu Y., Lewiston D., et al. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B (2007) in press
36. Hicks K.O., Ohms S.J., van Zijl P.L., et al. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 76 (1997) 894-903
37. Secomb T.W., Hsu R., Braun R.D., et al. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol 454 (1998) 629-634
38. Mulcahy R.T. Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res 44 (1984) 4409-4413
39. Koch C.J. The reductive activation of nitroimidazoles: Modification by oxygen and other redox-active molecules in cellular systems. In: Adams G.E. (Ed). Selective activation of drugs by redox processes (1990), Plenum Press, New York 237-247
40. Guise C., Wang A., Thiel A., et al. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol (2007) in press
41. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 6 (2006) 583-592
42. Denny W.A., and Wilson W.R. Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met Rev 12 (1993) 135-151
43. Helsby N.A., Ferry D.M., Patterson A.V., et al. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 90 (2004) 1084-1093
44. Helsby N.A., Wheeler S.J., Pruijn F.B., et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. Chem Res Toxicol 16 (2003) 469-478
45. Marshall R.S., and Rauth A.M. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res 46 (1986) 2709-2713
46. Wardman P., Priyadarsini K.I., Dennis M.F., et al. Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs. Br J Cancer 74 Suppl. XXVII (1996) S70-S74